Veracyte completed the acquisition of HalioDx from BPI France for $318m.

Veracyte, a genomic diagnostics company, completed the acquisition of HalioDx, an immuno-oncology diagnostic company, from BPI France for $318m. “The acquisition of HalioDx will further enable our long-term growth by providing key strategic capabilities to help us to execute on our powerful vision of improving outcomes for patients all over the world at every step of their journey. Our prior strategic acquisitions brought exclusive global access to a best-in-class diagnostic platform and a significantly expanded cancer testing menu. We believe HalioDx will help fuel our global growth by accelerating IVD test development and manufacturing operations in Europe and by expanding our scientific expertise into the emerging immuno-oncology field. Additionally, their commercial-stage colon cancer immune response test will broaden our testing menu to 8 of the top 10 cancers," Bonnie Anderson, Veracyte Cxecutive Chairwoman.